CMV DNAemia in patients treated with teclistamab. (A) Plot of the highest CMV DNA values by quantitative polymerase chain reaction in patients treated with teclistamab. CMV reactivation was defined as >500 IU/mL copies of CMV DNA. n = 12 patients. The mean ± standard error of the mean is shown. (B) ALC values (microliter) in patients with or without CMV DNAemia. The mean ± standard error of the mean is shown. ALC counts were obtained on days 1, 2, 3, 4, 5, 6, 7, 8, 14, 21, and 28 of cycle 1 of teclistamab. Analysis of variance, P < .0001. (C) Violin plots of ALC values (microliter) in 12 patients without CMV DNAemia and 11 patients with CMV DNAemia. The median ALC on the day of the first detectable CMV DNAemia or day 54 of teclistamab (median day of CMV reactivation) is highlighted with a solid black line. P = .21, not significant. (D) Swimmer plot of 11 patients who experienced CMV DNAemia with their treatment, time of CMV DNAemia clearance, and survival status. (E) Rate of infections other than CMV DNAemia in patients with and without CMV DNAemia. Fisher exact test, P = .003. PCR, polymerase chain reaction.